Abstract Purpose: To assess if pretargeting, using a combination of a recombinant bispecific antibody (bsMAb) that binds divalently to carcinoembryonic antigen (CEA) and monovalently to the hapten histamine-succinyl-glycine and a 
occurring within an hour (15, 16) . Importantly, too, the radiolabeled compounds used for pretargeting have minimal retention in the kidneys and, therefore, even tumor/kidney ratios with a pretargeted 111 In-labeled compound greatly exceed that of directly radiolabeled FabV (16, 17) . There are several reports of improved therapeutic responses with different pretargeting strategies (15, 16, 18, 19) . We are developing a bispecific antibody (bsMAb) pretargeting method with an antihapten antibody that recognizes a novel hapten [histaminesuccinyl-glycine (HSG); ref. 17]. Unlike most other bsMAb systems where the antihapten arm specifically binds to a radiolabeled chelate, the HSG hapten is not involved directly in the binding of the radionuclide, and therefore peptides could conceivably be synthesized with a wide variety compounds to bind radionuclides or, for that matter, other agents (e.g., paramagnetic, fluorescent, etc.) for disease detection or treatment. The core peptide structure (e.g., four to five amino acids) contains two HSG haptens to enhance and stabilize the hapten binding to the bsMAb in the tumor (20) . HSG peptides coupled with compounds capable of binding 99m Tc for imaging and 7,10-tetra-azacyclododecane-N,NV,N 00 ,N 000 -tetraacetic acid (DOTA) for use with 111 In, 177 Lu, or 90 Y have been described (16 -18) . In this report, in animal models, the toxicity associated with 90 Y-IgG and the pretargeted 90 Y-peptide was examined and therapeutic responses were compared.
Materials and Methods
Antibody and peptide reagents. The bsMAb, designated hBS14, was provided by IBC Pharmaceuticals, Inc. (Morris Plains, NJ). The binding properties and preparation of hBS14, a f80 kDa, fully humanized bsMAb that can divalently bind carcinoembryonic antigen (CEA) and monovalently bind HSG, have previously been described (21) . 125 I-hBS14 was prepared to a specific activity of f16 mCi/mg using 0.1 mL of 1.3 mmol/L tyrosine to terminate the reaction (21) . The radiolabeled product was >95% pure by size-exclusion high-performance liquid chromatography and instant TLC, and when mixed with a 10-fold mole excess of CEA (Scripps Laboratories, San Diego, CA), >95% of the product shifted to a higher molecular weight by high-performance liquid chromatography analysis.
Immunomedics, Inc. (Morris Plains, NJ) provided the DOTAconjugated humanized anti-CEA IgG, hMN-14 (22) , and the di-HSG-DOTA-peptide, IMP-241 (17). The DOTA-conjugated hMN-14 was prepared and radiolabeled as previously described (23) YCl 3 (Perkin-Elmer, Boston, MA). The final radiolabeled product had a specific activity of 5 mCi/mg. By sizeexclusion high-performance liquid chromatography, the product migrated as a well-defined single peak, and when excess CEA was added, >95% of the radiolabeled IgG migrated to a higher molecular weight. The HSG peptide was radiolabeled with 111 In or 90 Y, as previously described (17), to a specific activity of f590 and 1,640 Ci/mmol, respectively. Instant TLC indicated >97% of the radioactivity was bound, and when mixed with 10-fold mole excess of hBS14, >97% of the radioactivity shifted to the molecular size of the bsMAb; following the addition of CEA to this complex, >95% of the radiolabeled peptide and bsMAb shifted further to a higher molecular weight signifying the binding of the radiolabeled peptide to the bsMAb and the bsMAb to CEA.
Animal studies. All animal studies were done in accordance with the Institutional Animal Care and Use Committee -approved protocol. Hematologic toxicity was assessed in non-tumor-bearing, female, NIH Swiss mice (Taconic Farms, Inc., Germantown, NY). Groups of eight animals (5 weeks old; average body weight, f18.5 F 1.4 g) were given 100 to In-peptide using these same pretargeting conditions showed similar clearance and organ uptake in the NIH Swiss mice as in nude mice (not shown), and therefore similar toxicities would be expected. Prior to treatment, all mice were bled retroorbitally under local anesthesia, followed by weekly bleeding until recovery to baseline. A separate group of untreated animals also was monitored weekly. Blood drawn in a calibrated capillary tube (70 AL) was added to 50 AL of heparin followed by a 10-minute incubation in 1.0 mL of an ammonium chloride lysing buffer. The pellet was washed twice in PBS followed by resuspension in 1.0 mL of buffered formalin. The sample (30 AL) was read on a fluorescence-activated cell sorting scan (FACSCalibur, Becton Dickinson, San Jose, CA) that was previously calibrated using antibody standards (Becton Dickinson PharMingen, San Jose, CA) against mouse leukocyte markers. Total leukocyte counts derived for each treated animal were compared with the average leukocyte counts derived from all animals (n = 54) at the onset of study and expressed as the average percent change F SD for each treatment group.
Biodistribution and therapy studies were done in female athymic nude mice (NCr nu:NCI/Taconic, Taconic Farms). At f6 weeks of age, mice were implanted s.c. with a suspension of a CEA-producing, human colonic carcinoma cell line, GW-39 (24) . Two weeks later, baseline body weight and three-dimensional tumor size measurements were made and treatment was initiated. Y-IgG doses were supplemented with unlabeled DOTA-hMN-14 IgG so that a fixed protein dose of 50 Ag was given to all animals at each dose level. 90 Y activity was transferred to a 3-mL glass vial and read in a Capintec Model CRC-15R dose calibrator (Ramsey, NJ) that was previously calibrated against a National Institute of Standards and Technology standard using appropriate vessel/geometry controls. The volume required to deliver the prescribed dose was determined, drawn in syringes, and rechecked in the dose calibrator before injection.
Individual animals were marked, with five animals housed per cage. Cage bedding was changed several times the first week to remove the excreted radioactivity from the environment. Tumors and body weight were measured weekly and more frequently if required (e.g., rapid tumor progression or z10% loss in body weight). Animals with tumors exceeding 2.5 cm 3 or with evidence of morbidity (z20% loss in body weight) were euthanized, with tumors and kidneys placed in formalin for later histologic analysis. Monitoring continued for 34 weeks, at which time all surviving animals were necropsied. Any residual tumor masses and kidneys were placed in formalin for histologic analysis. All tissue samples were encoded to indicate their treatment group and embedded in paraffin. Five-to eight-micron sections were cut at different depths throughout the tumor and for the kidneys, sections were taken from the longitudinal midsection. Coded H&E-stained sections were read independently by a veterinary pathologist. Survival analysis was based on the time required for tumor to reach z2.5 cm 3 . Animals otherwise removed were censored from the survival analysis. Survival analysis was done using the GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA) and the log-rank test.
Whole-body clearance was determined by placing each of the treated animals in a dose calibrator, starting at 3 hours after the Research. and bled by cardiac puncture. Tumors and tissues were weighed, solubilized at 37jC in Solvable (Perkin-Elmer), and then counted in a gamma counter (Bremsstrahlung radiation) along with a standard prepared from the injected materials, thereby allowing for determination of decay-corrected (biological) % of injected dose/g and tumor/ nontumor ratios. The ACi/g effective data were used to derive area under the curve (AUC) and predicted average ACi/g activity in the tissues (i.e., dose rate). A trapezoidal model was used to define the clearance of radioactivity from the tumors and all normal tissues. The AUC includes an estimate of the residual activity either using the calculated effective half-life from the last data collection point or, as in the case with 90 Y-IgG, using the physical half-life of 90 Y. The average ACi/g was truncated at 96 hours for both treatments.
Results
Selecting optimized pretargeting conditions. Based on our prior experience in optimizing bsMAb-pretargeting procedures (25), a comparison was made for the pretargeting of the 111 Inpeptide using a bsMAb/peptide ratio of 10:1 with a 24-hour interval or 50:1 with a 48-hour interval. As shown in Table 1 , the % of injected dose/g of the hBS14 bsMAb in blood and tumor was reduced when the longer interval was used but because five times more bsMAb had been given at the 50:1 ratio, there was f2.4-fold more moles of bsMAb in the tumor compared with the 10:1 ratio when given at 24 hours. Nevertheless, the higher bsMAb dose did not increase tumor uptake of 111 In-peptide or have an appreciable effect on tumor/ nontumor ratio. Thus, all future studies were done using a 10:1 hBS14/peptide mole ratio with a 24-hour interval.
Biodistribution of the pretargeted 90 Y-peptide and 90 Y-hMN-14 immunoglobulin G. Figure 1 illustrates the biological clearance data for the pretargeted 90 Y-peptide and the 90 Y-anti-CEA IgG, as well as effective curves that are adjusted to reflect the administered activities for each treatment that subsequent data suggest are safely tolerated. Table 2 provides the calculated AUC and average ACi/g found in these tissues. The pretargeted peptide had a rapid uptake in the tumor, followed by a steady decline. Tumor uptake of the pretargeted peptide was more than 200 times higher than that observed with the 90 Y-peptide alone (not shown). At all times, tumor/nontumor ratios were highly favorable for the pretargeted 90 Y-peptide (e.g., at 3 hours, tumor/liver, kidney, and blood ratios were already 17.5 F 6.1, 4.1 F 0.7, and 9.1 F 4.2, respectively). In contrast, maximum tumor accretion of 90 Y-IgG occurred after several days, but as indicated in the effective curve, the ACi/g content in the tumors was relatively constant. At 24 hours, tumor/ nontumor ratios were 5.4 F 1.8, 5.7 F 1.8, and 1.4 F 0.2 for the liver, kidneys and blood, respectively. An assessment of the AUC data generated from the effective clearance curves that were adjusted to safely tolerated activities for each treatment suggests that pretargeting can deliver f1.7 times more radioactivity than 90 Y-IgG (Table 2 ). Based on the AUC ratios, pretargeting has an appreciable tumor/blood ratio advantage over 90 Y-IgG whereas 90 Y-IgG has a better tumor/kidney ratio. Pretargeting also maintains an average of nearly 2.5-fold more radioactivity in the tumor over a 96-hour period compared with 90 Y-IgG (48.8 versus 18.9 ACi/g). These differences are similar to those reported previously using the In-labeled peptide (16) (Fig. 2) . Six of the eight animals in the 200 ACi group and seven of the eight animals in the 175 ACi group experienced excessive loss in body weight within 2 weeks of treatment (with z90% decrease in leukocytes), which 90 Y-peptide. Evaluation of therapeutic response. Based on the hematologic toxicity data, we elected to test doses of 150 F 4 and 189 F 3 ACi. The f190 ACi dose was included because the body weights of the nude mice were f20% higher than the NIH Swiss mice, and therefore this higher dose may be tolerated. Because hematologic toxicity was not dose-limiting to the mice given f700 ACi of the pretargeted 90 Y-peptide and because earlier studies suggested as much as 1.0 mCi would be tolerated (16) , doses of 708 F 7 and 902 F 6 ACi were tested. Figure 3 shows the whole-body clearance of the 90 Yradioactivity from the animals given the pretargeted peptide or the IgG. In the pretargeting groups, nearly 80% of the total injected activity was eliminated within 3 hours, decreasing to a level similar to that found in the animals given 90 Y-IgG. After this initial loss of activity, the majority of the remaining activity cleared from the blood could be accounted for by 90 Y physical decay. However, animals given the pretargeted 90 Y-peptide had nearly 2-fold less activity in the body by 48 hours than that measured in the animals given 90 Y-IgG (e.g., 90.2 F 1.8 and 72.2 F 2.1 ACi for f190 and f150 ACi 90 Y-IgG injected activity compared with 54.4 F 10.5 and 48.1 F 11.7 ACi for the f900 and f700 ACi pretargeted 90 Y-peptide injected activity). This is likely a reflection of a gradual dissociation of a portion 90 Y-peptide bound to the bsMAb, with the peptide eliminated subsequently, but we cannot rule out localized peptide degradation.
All untreated animals and animals given 1.0 mCi of the 90 Ypeptide alone were removed from the study within 2 to 4 weeks because tumors exceeded 2.5 cm 3 (Fig. 4) . Most of the tumors in all the specific treatment groups also increased in size within the first 1 to 2 weeks, but by only f1.5-to 2-fold, and then tumor growth was arrested in nearly all animals. Only in the pretargeting groups was there evidence of substantial shrinkage of several of the tumor masses (three at 700 ACi dose and four at the 900 ACi dose), which essentially disappeared within 9 to 14 weeks.
At the end of the 34-week monitoring period, a total of six animals remained in the group of animals given 700 ACi of the pretargeted 90 Y-peptide. Two had no evidence of tumor whereas a residual mass of 0.1 cm 3 that was removed from one other animal showed no evidence of viable tumor, and therefore this treatment was credited for the tumor ablation in 3 animals. The other three animals had tumors of 1.0 to 2.3 cm 3 that had discrete areas of viable tumor, as well as pockets of previously killed cells. Another six animals were removed during the 34-week monitoring period due to tumor progression or excessive weight loss, and two were found dead at weeks 17 and 24. One animal removed from study at 19 weeks only had a residual mass of 0.043 cm 3 that showed no histologic evidence of viable tumor, and one found dead also had a residual mass too small to measure, but we were unable to obtain a specimen for histologic assessment. In sum, histologic examination indicated that 700 ACi of the pretargeted 90 Ypeptide resulted in the ablation of 4 of 12 tumors with an additional unconfirmed eradication of tumor. Kidneys were examined in 10 of 12 animals and revealed 3 to be normal, 6 with evidence of mild, multifocal glomerulonephritis, and 1 with mild to moderate multifocal perivascular lymphocytic infiltrates in the corticomedullary junction.
At the 900 ACi dose, five animals remained after 34 weeks. Whereas only one of the kidneys from the animals at 34 weeks had evidence of moderate changes, two animals removed earlier had evidence of end-stage renal disease (Fig. 5) . Thus, 900 ACi of the pretargeted 90 Y-peptide was considered an excessive dose and, therefore, although there were substantial antitumor responses in this group, including evidence of five cures, a formal assessment of the antitumor response in this group was considered inappropriate.
At 34 weeks, four animals remained in each of the 90 Y-hMN-14 IgG groups. Three tumors (one at the 150 ACi dose and two in the 190 ACi dose) had been stable at 0.330, 0.669, and 0.897 cm 3 for several months whereas the others had been progressing slowly toward the end of the study. Histology, however, revealed pockets of viable tumor in each of these tumors, and therefore no evidence of cures was found in any of the tumors of animals given the 90 ) indicated that the pretargeting procedure significantly improved survival (P < 0.04). In addition, the 700 ACi pretargeting dose resulted in the complete ablation of 4 of 12 and possibly 5 tumors whereas no cures were found in any of the 90 Y-hMN-14 IgG -treated control animals. Thus, the quantitative assessment of 90 Y uptake and retention in tumors, as well as evidence for significant improvements in therapeutic response, favors the use of pretargeting as a means of delivering radionuclides for cancer therapy.
Discussion
Several reports have found that pretargeted radionuclides, using either an avidin/biotin -based or a bsMAb-based approach, improve therapeutic response when compared with the same radionuclide delivered by a directly radiolabeled IgG or F(abV) 2 (15, 16, 19, 26 -30) . Many of the streptavidin-based studies have used 90 Y as the therapeutic radionuclide but this is the first report using a bsMAb pretargeting system where 90 Y has been studied in a solid tumor model and shown to have a therapeutic advantage, leading to tumor ablation in one third of the animals after a single dose of the radiolabeled peptide.
The most significant challenge in this study was how to objectively compare the efficacy of a directly targeted versus that of a pretargeted radionuclide when the dose-limiting toxicity for each of these treatments involves a different organ system. Hematologic toxicity was relatively mild in the pretargeted animals receiving 700 ACi of the 90 Y-peptide, suggesting that substantially higher doses could have been tolerated. However, when a large portion of the radionuclide is filtered through the kidneys, it is important to carefully assess the potential for renal toxicity. Severe renal toxicity associated with directly radiolabeled FabV (31) and diabodies (32) has been reported in mice but there is a considerably higher retention of these agents in the kidneys than that seen with 90 Ybiotin or 90 Y-peptide. There has been an extensive examination of renal toxicity associated with the use of radiolabeled somatostatin receptor peptides in rats and humans (33, 34) , which suggested that renal toxicity requires several months to be detected. Clinical studies using the NR-LU-10 IgG-streptavidin conjugate and 90 Y-biotin indicated that gastrointestinal toxicity was dose-limiting due to the uptake of 90 Y-biotin in the intestine but this was related to the specificity of the NR-LU-10 antibody for the gastrointestinal system (35, 36) . However, several patients also developed elevated serum creatinine z6 months after treatment. Thus, our preclinical study was designed to monitor animals for at least 6 months using direct histologic examination of the kidneys to assess toxicity. Renal toxicity was observed in 2 of 10 assessable animals given 900 ACi of the pretargeted 90 Y-peptide whereas other animals given this dose only had mild to moderate histologic changes, indicating that lower doses should be used. Although evidence for some degree of renal toxicity has previously been observed (26, 29) , other studies have not reported renal damage with doses as high as 1.0 mCi of pretargeted 90 Y-biotin, but these investigations may have been terminated prematurely or evaluated in only a small number of animals. Because the distribution of radionuclides can be monitored easily in patients by external scintigraphy, the risk for renal toxicity can be reduced by the use of dosimetry and with an understanding of radiation dose-response relationships. There is already considerable clinical experience in determining doseresponse relationships for a 90 Y-labeled somatostatin receptor peptide that will likely be similar for pretargeting procedures (37) . There is also a new multicompartment model for renal dosimetry that has been developed (38) and may improve the ability to relate renal toxicity with renal uptake of the injected radionuclides. Preclinical and clinical studies also suggest that radiation-induced renal toxicity can be reduced with the use of captopril, an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker (39, 40) . Thus, whereas careful assessment of renal accretion will be required for pretargeting procedures, it is clear from the preclinical evidence that at safely . Nude mice bearing GW-39 tumors averaging 0.34 cm 3 (n = 12) were injected i.v. with 244 Ag (3.05 nmol) of the bsMAb, followed 24 hours later with 700 ACi (0.305 nmol). Other animals were given 150 ACi (n = 12) or190 ACi (n =12) of 90 Y-DOTA-hMN-14 IgG (50 Ag). Controls include untreated animals (n = 11) or animals given 1.0 mCi (0.61nmol) of the tolerated doses, pretargeting can improve therapeutic responses at doses that do not result in renal damage and without the severe hematologic toxicity associated with directly radiolabeled IgG.
A dose of 700 ACi of the pretargeted 90 Y-peptide was a more effective treatment procedure than the directly radiolabeled antibody based on the survival data, the number of tumors cured by the treatment, and the targeting results showing a f1.7-fold higher AUC delivered to the tumor with a 2.5-fold higher average ACi/g at doses that we now consider to be equitoxic. Furthermore, the 700 ACi dose resulted only in a mild, multifocal glomerulonephritis that was similar to the histologic findings in animals given either 150 or 190 ACi of 90 Y-IgG. Importantly, too, the tumor/kidney AUC ratio was f5:1 for pretargeting. Therefore, these data collectively suggest that objective clinical responses might be achieved with this pretargeting procedure, assuming that these ratios can be attained.
This study and the work of others are highly supportive of continuing clinical studies with pretargeted radionuclides. Whereas the initial clinical experience in advanced metastatic colorectal cancer using the NR-LU-10-streptavidin/ 90 Y-biotin pretargeting procedure was disappointing (36) , clinical data continue to confirm the major finding of preclinical studies: pretargeting improves the tumor/nontumor radiationabsorbed dose ratios whereas the radiation-absorbed dose to tumors compares favorably to that reported for a directly radiolabeled antibody (41, 42) . However, it is likely that additional measures will need to be undertaken to achieve significant therapeutic effects in solid tumors. For example, there is evidence that when used to treat cancer locally or as minimal disease, directly radiolabeled antibodies are effective (1, 43 -45) ; thus, pretargeting perhaps could further improve responses in these settings. Pretargeting with bispecific humanized antibodies is also ideally suited for a variety of treatment options, including fractionated or multiple cycles of treatment, or even combinations with chemotherapy agents that themselves are myelosuppressive. Improved efficacy of combining pretargeting with gemcitabine (46) and paclitaxel (47) in animals bearing a colorectal and a medullary thyroid xenograft, respectively, has been reported. Fractionated or multiple cycles of pretargeted treatments will require the procedure to be less immunogenic than the streptavidin conjugates or fusion proteins tested to date (41, 42) . Here, a bsMAb pretargeting strategy using a humanized construct would have a distinct advantage. However, a thorough assessment of renal tolerance to fractionated or multiple cycles of treatment will be required.
In conclusion, this bsMAb pretargeting system has been shown to deliver higher doses of radioactivity to tumors in the model studied than directly radiolabeled IgG, thus supporting clinical testing to assess its prospects for improving the therapy of solid tumors.
